Association between maternal anxiety symptoms and bronchial hyperresponsiveness∗ in children
| OR (95% CI) for bronchial hyperresponsiveness (BHR) at 8½ y |
|||
|---|---|---|---|
| N BHR/no BHR (% with BHR) | Crude | Adjusted† | |
| Maternal anxiety symptoms at 18 wk | |||
| 1st quartile (0-2) | 197/1051 (15.8) | 1 (reference) | 1 (reference) |
| 2nd quartile (3-4) | 139/773 (15.2) | 0.96 (0.76-1.21) | 0.95 (0.75-1.20) |
| 3rd quartile (5-7) | 146/807 (15.3) | 0.97 (0.76-1.22) | 0.96 (0.76-1.21) |
| 4th quartile (8-16) | 120/555 (17.8) | 1.15 (0.90-1.48) | 1.15 (0.89-1.48) |
| P (trend) | .39 | .42 | |
| Maternal anxiety symptoms at 32 wk | |||
| 1st quartile (0-2) | 190/1004 (15.9) | 1 (reference) | 1 (reference) |
| 2nd quartile (3-4) | 143/804 (15.1) | 0.94 (0.74-1.19) | 0.95 (0.75-1.21) |
| 3rd quartile (5-7) | 158/871 (15.4) | 0.96 (0.76-1.21) | 0.97 (0.77-1.22) |
| 4th quartile (8-16) | 130/618 (17.4) | 1.11 (0.87-1.42) | 1.14 (0.89-1.46) |
| P (trend) | .50 | .41 | |
∗
Bronchial hyperresponsiveness defined as PD20 <1.2 mg methacholine.
†
Adjusted for sex, preterm delivery, multiple birth, number of siblings, maternal age, maternal education, maternal history of asthma and allergy, prenatal tobacco smoke exposure, and problems during pregnancy (diabetes, hypertension, steroid intake).